Navigation Links
St. Jude Study Shows Effectiveness of Peramivir in Prevention of,Mortality in Mouse Model of Avian Influenza H5N1 Virus Infection

amivir, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future clinical trials may not have positive results, that we may not be able to complete successfully the Phase IIb trial for Fodosine(TM) that is currently planned to be pivotal, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not reach favorable agreements with potential pharmaceutical and biotech partners for further development of its product candidates, that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, current reports on Form 8-K which identify important factors that could cause the actual results to differ materially from those contained in the projections or forward-looking statements.

    Contact:

    BioCryst Pharmaceuticals, Inc.

    Jonathan M. Nugent

    V.P. Corporate Communications

    (205) 444-4633

CONTACT: Jonathan M. Nugent, V.P. Corporate Communications of BioCrystPharmaceuticals, Inc., +1-205-444-4633

Web site: http://www.biocryst.com/'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:8/30/2015)... Massachusetts y LONDRES, August 30, 2015 /PRNewswire/ ... ofrece una visión holística de l ... todo el trayecto   ... hoy el debut europeo de IntelliSpace Cardiovascular , ... que ofrece sofisticadas herramientas para acceder, analizar y compartir ...
(Date:8/28/2015)... , Aug. 28, 2015  Delays in ... projects can slow down the decision-making process, resulting ... therefore, absolutely critical for biopharmaceutical companies to develop ... approval process for quicker and more meaningful insights. ... Best Practices, LLC, nearly three-quarters of benchmarked study ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Originally discovered by Welfide ... Pharmaceutical Industries, Ltd) as an inflammatory drug, pranoprofen ... Pharmaceutical Co., Ltd under the trade name of ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
... NEW YORK, April 28, 2011 Reportlinker.com ... is available in its catalogue: ... Healthcare System and Drug Regulatory Overview: Cost-containment ... http://www.reportlinker.com/p0487111/Pharmaceutical-Key-Trends-2011---Healthcare-System-and-Drug-Regulatory-Overview-Cost-containment-and-regulatory-pressures-intensify.html ...
... 28, 2011 West Pharmaceutical Services, Inc. (NYSE: ... quarter of 2011.  Summary comparative results were as follows:($ millions, ... 295.4 , $ 274.7Gross Profit , 88.0 , 82.2Reported Operating ... 30.7 , 29.5Reported Diluted EPS , $ 0.56 , $ ...
Cached Medicine Technology:Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 2Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 3Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 4Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 5Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify 6West Announces First Quarter 2011 Results 2West Announces First Quarter 2011 Results 3West Announces First Quarter 2011 Results 4West Announces First Quarter 2011 Results 5West Announces First Quarter 2011 Results 6West Announces First Quarter 2011 Results 7West Announces First Quarter 2011 Results 8West Announces First Quarter 2011 Results 9West Announces First Quarter 2011 Results 10West Announces First Quarter 2011 Results 11West Announces First Quarter 2011 Results 12West Announces First Quarter 2011 Results 13West Announces First Quarter 2011 Results 14
(Date:8/31/2015)... Scotch Plains, NJ (PRWEB) , ... August 31, ... ... in practice! Garden State Urology was formed in 2008, the result of a ... on the principle that by working cooperatively, they could provide more cost-effective and ...
(Date:8/31/2015)... , ... August 31, 2015 , ... NJ Top Docs Presents, Dr. Michael Betsy! ... in Park Ridge, New Jersey, Dr. Michael Betsy graduated from Don Bosco Prep in 1990 ... served as team captain in both sports in his senior year. He was inducted ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... Dr. ... it may be prevented during Amblyopia Awareness Month. Only a comprehensive eye examination can ... most common cause of visual impairment among children, affecting approximately 2 to 3 out ...
(Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications ... today that it has officially launched a new website and company identity ( ... refresh are more closely aligned with the company’s strategic vision for growth and ...
(Date:8/31/2015)... Moscow, PA (PRWEB) , ... August 31, 2015 , ... ... to provide visitors and retailers with even more relevant and easy-to-find information on their ... , “Our website has always been an important way for us to share ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Garden State Urology! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 2Health News:NJ Top Docs Presents, Dr. Michael Betsy! 3Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 2Health News:Renowned Eye Surgeon Dr. Stewart Shofner Shares Information about the Causes of Lazy Eye During Amblyopia Awareness Month 3Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Three Bakers Gluten Free Bakery Announces Launch of New Website 2
... fare more likely to act out at 7, 10, study ... exposed to violent television -- even cartoons -- are more ... Their findings don,t definitively prove that TV makes children act ... to the researchers. But the link does appear solid in ...
... ORLANDO, Fla. -- If you go to the hospital within ... a heart attack, your chances of getting proper treatment are ... 12 hours before seeking treatment, according to results presented today ... Fla. , This research should emphasize to patients that getting ...
... For the next two weeks,the "Help is Here ... of Southern California, attempting to help uninsured and,under-insured ... stop will,be from 10 a.m. until 2 p.m. ... CA., This marks the seventh time the ...
... Nov. 5 /PRNewswire/ - Halogen Software Inc., the ... software,today announced the third quarter of 2007 was ... in almost every category with nearly,50 percent year-over-year ... "Maximizing employee performance is a high priority ...
... role for a cancer-prevention gene in the response to drug ... suppressor gene, also known as the guardian of the genome, ... Mutations in the gene are associated with a high incidence ... give rise to tumours. , In childhood cancers such as ...
... , , MONDAY, Nov. 5 (HealthDay News) -- It turns out ... control in colder weather, heart experts say. , But the ... Association annual meeting, in Orlando, Fla., is not exactly new. ... pressure tends to be a little bit harder to control ...
Cached Medicine News:Health News:TV Violence May Spur Aggression in Boys 2Health News:TV Violence May Spur Aggression in Boys 3Health News:Mayo Clinic identifies new risk factor for heart attack patients 2Health News:'Help is Here Express' Bus Tour in California to Help Fire Victims Access Prescription Medicines 2Health News:'Help is Here Express' Bus Tour in California to Help Fire Victims Access Prescription Medicines 3Health News:Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue 2Health News:Halogen Software Achieves Most Successful Quarter in Company History - Includes Record Year-Over-Year Overall and License Revenue 3Health News:Blood Pressure Tougher to Tame in Winter 2
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... only catheter of its kind, the ... collects real-time cardiac electrical information, translating ... With 64 electrodes, this unique tool ... than 3,000 points of electrical data ...
... The St. Jude Medical® Pacing System Analyzer ... solution for implantation testing, programming and interrogation ... as an easy-to-use accessory to the St. ... testing by obtaining measurements of intrinsic P- ...
Medicine Products: